[18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice.

abstract：:We describe a patient with unusually indolent hepatosplenic gammadelta T cell lymphoma characterised by severe lassitude and high fever. No significant responses were obtained to a range of chemotherapeutic and biological agents. 2'-deoxycoformycin (dCF), however, produced a dramatic and sustained clinical and histolo...

journal_title：Leukemia & lymphoma

authors： Grigg AP

更新日期：2001-08-01 00:00:00

abstract：:Two cases of polycythemia vera (PV) had transition to a hematological condition compatible with chronic neutrophilic leukemia (CNL) 17 and 8 years after diagnosis, respectively. One patient was treated with carboquone followed by hydroxyurea (HU) and the other with HU during PV phase. On transition, both had neutrophi...

journal_title：Leukemia & lymphoma

authors： Higuchi T,Oba R,Endo M,Harada H,Mori H,Niikura H,Omine M,Fujita K

更新日期：1999-03-01 00:00:00

abstract：:Fludarabine is an active agent for the treatment of Waldenstrom's macroglobulinemia (WM) and its combination with cyclophosphamide has been effective in many patients with low-grade lymphoma and chronic lymphocytic leukemia. Based on these data, we administered the combination of fludarabine (25 mg/m2 i.v. day 1-3) an...

journal_title：Leukemia & lymphoma

authors： Dimopoulos MA,Hamilos G,Efstathiou E,Siapkaras I,Matsouka C,Gika D,Grigoraki V,Papadimitriou C,Mitsibounas D,Anagnostopoulos N

更新日期：2003-06-01 00:00:00

abstract：:Chronic myelogenous leukaemia (CML) is one of the most intensively studied human malignancies. It has been the focus of major efforts to develop potent drugs for several decades, but until recently cure rates remained low. A breakthrough in CML therapy was very likely accomplished with the clinical introduction of STI...

journal_title：Leukemia & lymphoma

authors： Feller SM,Tuchscherer G,Voss J

更新日期：2003-03-01 00:00:00

abstract：:Although targeted deep sequencing of cell-free DNA (cfDNA) was recently used to investigate tumor somatic mutations in particular subtypes of non-Hodgkin lymphomas (NHLs), the immense genetic heterogeneity across subtypes poses a hurdle to design a universal gene panel applicable for diverse subtypes of NHLs. We desig...

journal_title：Leukemia & lymphoma

authors： Shin SH,Kim YJ,Lee D,Cho D,Ko YH,Cho J,Park WY,Park D,Kim SJ,Kim WS

更新日期：2019-09-01 00:00:00

abstract：:An international workshop, under the auspices of Group d'Etude des Lymphomes de l'Adulte (GELA) took place in Deauville, France, in April 3-4, 2009. The European experts with a published or personal experience on interim-PET in lymphoma were invited to the meeting. The aim of the workshop was twofold: (1) to reach a c...

journal_title：Leukemia & lymphoma

authors： Meignan M,Gallamini A,Meignan M,Gallamini A,Haioun C

更新日期：2009-08-01 00:00:00

abstract：:Elevated serum free light chains (FLCs) have been associated with an unfavorable prognosis in diffuse large B-cell lymphoma (DLBCL). The aim of this study was to determine the clinical relevance of a quantitative assessment of intact circulating immunoglobulin (Ig), using serum Ig heavy chain/light chain pair (HLC) me...

journal_title：Leukemia & lymphoma

authors： Jardin F,Delfau-Larue MH,Molina TJ,Copie-Bergman C,Brière J,Petrella T,Canioni D,Fabiani B,Jais JP,Figeac M,Leroy K,Mareschal S,Salles GA,Coiffier B,Delarue R,Peyrade F,Bosly A,André M,Ketterer N,Haioun C,Tilly H

更新日期：2013-09-01 00:00:00

abstract：:The aim of this study was to determine the expression of Gravin (a tumor suppressor gene belonging to the A kinase anchoring protein family) in samples of acute leukaemia and to explore its association with the prognosis. The study group consisted of 162 people (137 patients with acute leukaemia and 25 volunteers as c...

journal_title：Leukemia & lymphoma

authors： Yildirim M,Paydas S,Tanriverdi K,Seydaoglu G,Disel U,Yavuz S

更新日期：2007-06-01 00:00:00

abstract：:Chronic lymphocytic leukemia (CLL) is at present an incurable disease. All of the drugs used in the treatment of CLL induce apoptosis in the cells, and in vitro responses to glucocorticoid or analogs correlate with in vivo sensitivity to these agents. Since CLL lymphocytes accumulate rather than proliferate, the idea ...

journal_title：Leukemia & lymphoma

authors： McConkey DJ,Chandra J

更新日期：1999-05-01 00:00:00

abstract：:A possible role for DNA mismatch repair defects and microsatellite instability (MSI) in the pathogenesis of a number of B-cell lymphoproliferative disorders has recently been debated. To gain further insight into the impact of MSI on B-CLL, we evaluated samples from a series of 982 patients using the mono-satellite ma...

journal_title：Leukemia & lymphoma

authors： Sellick GS,Lubbe SJ,Matutes E,Catovsky D,Houlston RS

更新日期：2007-07-01 00:00:00

abstract：:Myeloablative doses of busulfan (Bu) with fludarabine (Flu) have reduced toxicity, however, limited by an increased relapse rate. We aimed to improve outcome of Flu-Bu regimen by augmentation with thiotepa (TT) (10 mg/kg). Eighty-nine patients with AML, 44 patients conditioned with Flu-Bu (group 1), and 45 patients au...

journal_title：Leukemia & lymphoma

authors： Sheth V,Nachmias B,Grisariu S,Avni B,Or R,Shapira M

更新日期：2019-03-01 00:00:00

abstract：:We examined the effect of high-dose methylprednisolone (HDMP) on blast reduction rate and compared it to conventional dose steroid treatment, administered during the first 7+ days of the induction remission period in patients with acute lymphoblastic leukemia (ALL). In our previous randomized study, the event free sur...

journal_title：Leukemia & lymphoma

authors： Yetgin S,Cetin M

更新日期：2003-03-01 00:00:00

abstract：:Survival of chronic lymphocytic leukemia (CLL) cells in vivo is supported by the tissue microenvironment, which includes components of the extracellular matrix. Interactions between tumor cells and the extracellular matrix are in part mediated by CD44, whose principal ligand is hyaluronic acid. Here, we show that CD44...

journal_title：Leukemia & lymphoma

authors： Herishanu Y,Gibellini F,Njuguna N,Hazan-Halevy I,Farooqui M,Bern S,Keyvanfar K,Lee E,Wilson W,Wiestner A

更新日期：2011-09-01 00:00:00

abstract：:Ibrutinib increases the risk of atrial fibrillation (AF), but the associated risk factors are not clearly defined. We performed retrospective review of ibrutinib-treated patients in a large academic practice to identify risk factors for new-onset AF. Variables with p-values <.05 in logrank analysis were included as pa...

journal_title：Leukemia & lymphoma

authors： Lentz R,Feinglass J,Ma S,Akhter N

更新日期：2019-06-01 00:00:00

abstract：:The outcome of conventional therapy in adult acute lymphoblastic leukaemia (ALL) is disappointing. Allogeneic bone-marrow transplantation may give improved results but has only limited applicability because of the lack of a suitable donor in most patients. We have therefore investigated intensive chemotherapy and chem...

journal_title：Leukemia & lymphoma

authors： Mcmillan AK,Gribben JG,Linch DC,Anderson C,Richards JD,Goldstone AH

更新日期：1990-01-01 00:00:00

abstract：:A man in late middle age presented with fever, systemic symptoms, raised inflammatory markers and anaemia of chronic disease. Despite two months of investigation, the diagnosis of a haematological malignancy was made only at autopsy. ...

journal_title：Leukemia & lymphoma

authors： Gabriel IH,Chong N,Rice A,Negus R,Bain BJ

更新日期：2007-07-01 00:00:00

abstract：:Classic Hodgkin's Disease (cHD) is a lymphoid neoplasia characterized by a few malignant Hodgkin and Reed-Sternberg (H-RS) cells embedded in an abundant background of non-tumor cells. In this context, fibrosis is a common morphologic feature of HD lesions, being found more frequently in cHD subtypes. The clinical and ...

journal_title：Leukemia & lymphoma

authors： Aldinucci D,Lorenzon D,Olivo K,Rapanà B,Gattei V

更新日期：2004-09-01 00:00:00

abstract：:Existing prognostic tools for HIV + diffuse large B-cell lymphoma (DLBCL) fail to accurately predict patient outcomes. To develop a novel prognostic algorithm incorporating molecular tumor characteristics and HIV disease factors, we included 80 patients with HIV-related DLBCL diagnosed between 1996 and 2007. Immunohis...

journal_title：Leukemia & lymphoma

authors： Chao C,Silverberg MJ,Chen LH,Xu L,Martínez-Maza O,Abrams DI,Zha HD,Haque R,Said J

更新日期：2018-02-01 00:00:00

abstract：:Non-Hodgkin lymphoma (NHL) remains one of the most common cancers in the US, with survival dependent on the type and stage of disease. B-cell lymphomas account for approximately 85% of all cases of NHL, and are commonly treated with chemotherapy, or monoclonal antibodies (mAbs) that target CD20 antigens on the surface...

journal_title：Leukemia & lymphoma

authors： Maloney D,Morschhauser F,Linden O,Hagenbeek A,Gisselbrecht C

更新日期：2010-08-01 00:00:00

abstract：:The Rai and Binet staging systems, which are used as standard methods for evaluating the prognosis of chronic lymphocytic leukemia (CLL), have some restrictions in identifying patients with early-stage CLL who will progress rapidly. To solve this defect, other prognostic parameters have become important in recent year...

journal_title：Leukemia & lymphoma

authors： Hancer VS,Kose M,Diz-Kucukkaya R,Yavuz AS,Aktan M

更新日期：2011-01-01 00:00:00

abstract：:This study was planned as a phase 3 trial to investigate low-dose fludarabine with or without darbepoetin alfa in older patients with previously untreated or treated chronic lymphocytic leukemia (CLL) and comorbidity. Due to slow recruitment, the study was terminated prematurely after accrual of 97 patients who, on av...

journal_title：Leukemia & lymphoma

authors： Goede V,Busch R,Bahlo J,Chataline V,Kremers S,Müller L,Reschke D,Schlag R,Schmidt B,Vehling-Kaiser U,Wedding U,Stilgenbauer S,Hallek M

更新日期：2016-01-01 00:00:00

abstract：:Patients with multiple myeloma who are refractory or intolerant to both bortezomib and lenalidomide have a poor prognosis. Next-generation therapies carfilzomib and pomalidomide have shown promising activity in this dual refractory population. Here we describe the clinical characteristics and ascertain the effects of ...

journal_title：Leukemia & lymphoma

authors： Wang TF,Ahluwalia R,Fiala MA,Trinkaus KM,Cox DP,Jaenicke M,Moliske CC,Carson KR,Wildes TM,Tomasson MH,Stockerl-Goldstein KE,Vij R

更新日期：2014-02-01 00:00:00

abstract：:Anamorsin is a cell-death-defying factor, which was originally isolated as a molecule that conferred resistance to apoptosis induced by growth factor starvation. In order to evaluate anamorsin expression levels in malignant lymphoma, we immunostained paraffin-embedded sections with anti-anamorsin monoclonal antibodies...

journal_title：Leukemia & lymphoma

authors： Shizusawa T,Shibayama H,Murata S,Saitoh Y,Sugimoto Y,Matsumura I,Ogawa H,Sugiyama H,Fukuhara S,Hino M,Kanamaru A,Yamauchi A,Aozasa K,Kanakura Y

更新日期：2008-01-01 00:00:00

abstract：:Monoclonal proteins (paraproteins) may be detected in the sera in approximately 1% of the general population and are frequently associated with peripheral neuropathy. Paraproteinemic neuropathy (PPN) is most commonly associated with monoclonal gammopathy of undetermined significance, and may also occur in the context ...

journal_title：Leukemia & lymphoma

authors： Zivković SA,Lacomis D,Lentzsch S

更新日期：2009-09-01 00:00:00

abstract：:We describe a patient with extranodal (pulmonary) marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) who was refractory to treatment with cytotoxic chemotherapy. After a single four-week course of rituximab she had significant regression of pulmonary lesions and remains progression free 19 month...

journal_title：Leukemia & lymphoma

authors： Chong EA,Svoboda J,Cherian S,Andreadis C,Downs LH,Zhuang H,Alavi A,Tsai DE,Schuster SJ

更新日期：2005-09-01 00:00:00

abstract：:CXCR4 directs chronic lymphocytic leukemia (CLL) trafficking within protective tissue niches, and targeting CXCR4 with plerixafor may enhance drug sensitivity. We performed a phase 1 dose escalation study of plerixafor (NCT00694590) with rituximab in 24 patients with relapsed/refractory CLL. Patients received rituxima...

journal_title：Leukemia & lymphoma

authors： Andritsos LA,Byrd JC,Cheverton P,Wu J,Sivina M,Kipps TJ,Burger JA

更新日期：2019-12-01 00:00:00

abstract：:Lymphoblastic lymphoma (LBL) is a neoplasm of precursor B- or T-lymphocytes, and primary skin involvement is uncommon. The aim of the study was to review all reported primary cutaneous (PC)-LBLs and to examine three new cases to better characterize this neoplasm. Two of our patients showed a pre-B phenotype (PC-B-LBL)...

journal_title：Leukemia & lymphoma

authors： Vezzoli P,Novara F,Fanoni D,Gambini D,Balice Y,Venegoni L,Paulli M,Crosti C,Berti E

更新日期：2012-10-01 00:00:00

abstract：:Rapamycin and its derivatives have been proposed in the treatment of leukemia based on their cytostatic effects, but their possible role in differentiation therapy is less explored. The aim of the present study was to investigate the possible beneficial effects of the combination of rapamycin and dimethyl sulfoxide (D...

journal_title：Leukemia & lymphoma

authors： Lalic H,Lukinovic-Skudar V,Banfic H,Visnjic D

更新日期：2012-11-01 00:00:00

abstract：:The purpose of this study was to explore the characteristics and functions of BH3-only proteins Puma, Noxa and Bim in the prognosis, therapy and drug resistance of chronic lymphocytic leukemia (CLL). Puma, Noxa and Bim mRNAs were evaluated by real-time quantitative reverse transcriptase-polymerase chain reaction, and ...

journal_title：Leukemia & lymphoma

authors： Zhu HJ,Liu L,Fan L,Zhang LN,Fang C,Zou ZJ,Li JY,Xu W

更新日期：2013-12-01 00:00:00

abstract：:Following the introduction of the WHO classification of chronic myeloproliferative disorders (MPDs), after approximately 5 years, a critical reappraisal appears to be warranted. Retrospective clinico-pathological evaluations conducted in the meantime, as well as the detection of new biomarkers, may aid in testing the ...

journal_title：Leukemia & lymphoma

authors： Thiele J,Kvasnicka HM

更新日期：2006-03-01 00:00:00